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Non-invasive in vivo determination 
of viable islet graft volume by 111In-
exendin-3
Wael A. Eter, Inge Van der Kroon, Karolina Andralojc, Mijke Buitinga, Stefanie M. A. 
Willekens, Cathelijne Frielink, Desiree Bos, Lieke Joosten, Otto C. Boerman, Maarten Brom  
& Martin Gotthardt
Pancreatic islet transplantation is a promising therapy for patients with type 1 diabetes. However, 
the duration of long-term graft survival is limited due to inflammatory as well as non-inflammatory 
processes and routine clinical tests are not suitable to monitor islet survival. 111In-exendin-SPECT 
(single photon emission computed tomography) is a promising method to non-invasively image 
islets after transplantation and has the potential to help improve the clinical outcome. Whether 111In-
exendin-SPECT allows detecting small differences in beta-cell mass (BCM) and measuring the actual 
volume of islets that were successfully engrafted has yet to be demonstrated. Here, we evaluated the 
performance of 111In-exendin-SPECT using an intramuscular islet transplantation model in C3H mice. 
In vivo imaging of animals transplanted with 50, 100, 200, 400 and 800 islets revealed an excellent 
linear correlation between SPECT quantification of 111In-exendin uptake and insulin-positive area of 
islet transplants, demonstrating that 111In-exendin-SPECT specifically and accurately measures BCM. 
The high sensitivity of the method allowed measuring small differences in graft volumes, including 
grafts that contained less than 50 islets. The presented method is reliable, convenient and holds great 
potential for non-invasive monitoring of BCM after islet transplantation in humans.
Transplantation of islets of Langerhans is a promising treatment for patients with type 1 diabetes (T1D). The 
short-term results of islet transplantation in normalizing blood glucose levels are encouraging1. However, the 
rate of insulin-independency drops to less than 15% after 5 years2. Although the loss of transplanted beta-cells 
quickly renders patients insulin-dependent in a life-time perspective, the remaining graft function still exerts a 
positive effect on glucose homeostasis, reducing late complications and further progression of micro-vascular dis-
eases3. Furthermore, the islet grafts lower the amount of insulin required to maintain normoglycemia preventing 
potentially lethal, severe hypoglycemia. However, in view of the considerable side effects caused by the immuno-
suppressive therapy required to prevent graft rejection, improved survival of the transplanted islet is desirable. 
In order to optimize islet replacement therapy and to prevent loss of graft function, numerous approaches are 
currently under investigation, including modified immunosuppressive treatments4, 5 and islet encapsulation strat-
egies6, 7 treatment with growth factors and other hormones, as well as alternative sources for beta-cells (i.e. stem 
cells, tissue bioengineering)8–11. In order to monitor the graft volume and optimize new strategies for beta-cells 
replacement a non-invasive technology to visualize viable transplanted islets in vivo is warranted. Such a method 
should be quantitative and sensitive in order to allow the detection of small changes in the number of surviving 
islets.
A promising approach to visualize transplanted islets in vivo has been demonstrated by Saudek et al., 
using Magnetic Resonance Imaging (MRI). The group described MRI of islets that had been labeled with 
super-paramagnetic iron oxide particles (SPIOs) prior to transplantation12. The feasibility of longitudi-
nal non-invasive monitoring of islet transplants was further demonstrated in animal models by Evgenov and 
co-workers, successfully monitoring islet transplants for up to 188 days after surgery13. Pre-labeling of the islets 
with SPIOs is therefore a promising method with clinical potential14.
Alternatively, radionuclide imaging modalities were used because of their high detection sensitivity of trans-
planted islets. First results of PET imaging of an islet graft were published in 2006, using islets which were trans-
fected with an insulin promoter-dependent reporter gene that leads to trapping of the PET probe 18F-FHBG 
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in islet grafts15. In another experiment, islets were pre-labeled with 18F-fluorodeoxyglucose (18F-FDG) and 
post-transplantation events could be monitored for up to 6 hours after transplantation16.
More recently, specific targeting of beta-cells after in vivo injection of radiolabeled exendin followed by SPECT 
imaging was reported as a promising strategy to non-invasively visualize and quantify BCM in the pancreas of 
rodents, as well as in healthy and diabetic individuals17, 18. Similar exendin-based radiotracers were applied for 
non-invasive imaging of islet grafts in rodent transplantation models as well as in human skeletal muscle19–21. 
Although the use of such tracers in a clinical setting of islet transplantation is highly warranted, establishing the 
correlation between true BCM and the uptake of the radiotracer in vivo is the essential validation step before such 
studies should be conducted in humans. Such decisive studies have not been performed for GLP-1R imaging of 
islet transplants.
In the present study, we measured the uptake of 111In-exendin-3 in transplants consisting of different amounts 
of islets in the calf muscles of C3H mice by non-invasive SPECT imaging in vivo and validated 111In-exendin as a 
quantitative biomarker for assessment of transplanted beta-cell volume.
Results
111In-exendin accumulation in the muscle co-localizes with islet transplants. To check whether 
111In-exendin-3 signal originates from transplanted islets, C3H mice were transplanted with 800 islets in the 
calf muscle and were injected with 111In-exendin-3 four weeks after transplantation, where accumulation of the 
radiotracer in the islets becomes reproducible22. Autoradiographical analysis of muscle sections showed tracer 
accumulation in well localized regions of the tissue (Fig. 1A) and immunostaining for insulin confirmed that the 
radioactive signal originated from the islets (Fig. 1B).
111In-exendin uptake by transplanted islets correlates linearly with BCM. 111In-exendin-3 uptake 
in grafts containing various amounts of islets was detected and clearly delineated by SPECT signal (Fig. 2A). 
Quantitative analysis of SPECT signal originating from the transplant revealed differences in 111In-exendin-3 
accumulation depending on the number of initially transplanted islets, where the uptake was 5.9 kBq ± 2.4, 
22.9 kBq ± 4.8, 30.1 kBq ± 10.1, 60.9 kBq ± 9.8 and 88.7 kBq ± 11.5, in muscles transplanted with 50, 100, 200, 
400 and 800 islets, respectively (Fig. 2B). Immunohistochemical determination of graft volume was performed 
in all groups of mice (Fig. 2C). Plotting of SPECT data against the insulin staining volume revealed an excellent 
linear correlation between 111In-exendin uptake and transplant size (pearson r = 0.89).
Discussion
The aim of this study was to evaluate the relation between 111In-exendin uptake in islet transplants compared to 
actual BCM in a muscle model of islet transplantation. Tracer uptake and beta-cell volume showed an excellent 
linear correlation. In addition, reliable visualization of transplants consisting of low numbers of islets indicates 
towards high sensitivity of this method. This high sensitivity in combination with the excellent correlation of 
BCM and tracer uptake demonstrate the potential of this method to quantify small differences in viable beta-cell 
volume.
Previously, imaging of liver islet transplants using 64Cu-labelled exendin has been demonstrated in NOD/
SCID mice19. Twelve days follow-up of the grafts revealed significantly higher uptake of 64Cu-labeled exendin-4 
in the liver of transplanted animals when compared to the control group. Here, we used the skeletal muscle trans-
plantation as a highly controlled model for histological verification of the insulin positive area (which is chal-
lenging in the liver transplantation model given that islets are distributed throughout a large part of the organ), a 
Figure 1. 111In-exendin-3 uptake in the skeletal muscle is co-localized with islet transplants. (A) 
Autoradiography of muscle sections shows local accumulation of 111In-exendin-3 (black arrows), the limits of 
the muscle section are shown by the dashed line. (B) Immunostaining of the corresponding autoradiography 
section shows co-localization between beta-cells (brown) and 111In-exendin-3.
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prerequisite enabling us to, for the first time, reveal an excellent linear correlation between the actual numbers of 
beta-cells that were successfully engrafted, and the uptake of the tracer in the islet grafts.
Recently, it was reported that injection of 123I-IBZM enables the quantification of BCM in islet grafts, 
where tracer uptake could be linearly correlated with graft volume23, 24. However, a far lower correlation was 
observed between 123I-IBZM uptake and insulin positive graft volumes when compared to 111In-exendin, indi-
cating that GLP-1R could allow more accurate assessments of islet graft survival. Moreover, our data indicate 
that 111In-exendin has a much higher sensitivity for detection of islet grafts when compared to 123I-IBZM as 
we could easily visualize islet grafts after transplantation of 50 islets while 1000 islets were needed for in vivo 
visualization by IBZM. In fact, more than 50% of the islets could be lost in the first days after transplantation25, 
indicating that 111In-exendin-SPECT was able to detect grafts containing far less than the 50 islets being initially 
transplanted. The superior detection sensitivity of 111In-exendin-SPECT could be explained by the higher abun-
dance of the GLP-1R on the surface of the beta-cells when compared to the dopamine 2 receptor21, 23. Hence, 
111In-exendin-SPECT has the potential to detect small grafts even after post transplantation beta-cell loss. This 
enables the possibility to evaluate and optimize treatment to preserve the remaining islets in patients that became 
insulin dependent after islet transplantation, helping to preserve their positive effect on glucose homeostasis.
Figure 2. Uptake of 111In-exendin by islet transplants is in linear correlation with transplant size. (A) SPECT 
imaging detected the grafts initially transplanted with 50, 100, 200, 400 or 800 islets with high sensitivity, 4 
weeks after transplantation (white arrows). (B) 111In-exendin uptake (expressed in kilobecquerels, kBq) was 
dependent on transplant size (n = 4–5). Data are shown as means ± SEM (n = 5). (C) SPECT signal (expressed 
in kBq) correlated linearly with graft insulin-positive volume (µm3). (Pearson r = 0.89, 95% confidence interval 
shown as a dotted line).
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The skeletal muscle was selected as a transplantation site to evaluate whether 111In-exendin-3 can be used 
to monitor beta-cell volume after transplantation. So far, this site has been used for islet transplantation in an 
experimental setting in small animal models and in a few patients20. In the clinical setting, intra-portal islet trans-
plantation still predominates26. The ability to detect islet transplants in the liver with exendin-3 has previously 
been demonstrated in a proof of concept study in mice19. Further studies are warranted to assess whether our 
finding that the 111exendin-3 uptake corresponds to the beta-cell volume after transplantation is also valid after 
intrahepatic islet transplantation.
In conclusion, we have demonstrated for the first time that 111In-exendin-3 can be used to determine beta-cell 
volume after intramuscular islet transplantation. 111In-exendin-3 uptake linearly correlates with the amount of 
living beta-cells, and allows the detection of islet grafts consisting of less than 50 islets by SPECT imaging. Our 
data indicates that this approach holds great potential for accurate and sensitive quantification of viable beta-cells 
in a transplantation setting. Clinical studies evaluating the potential of this promising radiotracer for imaging of 
islets grafts in humans are under preparation.
Research Design and Methods
Animals. Female C3H/HeNCrl mice (22–30 g) were purchased from Charles River (Calco, Itlay). All exper-
iments were conducted in accordance with Radboud University guidelines on humane care and use of labora-
tory animals and were approved by the Animal Ethical Committee of the Radboud University, Nijmegen, The 
Netherlands.
Pancreatic islet isolation and transplantation. Pancreatic islets were isolated from 6–8 weeks old 
mice by a collagenase digestion method. Briefly, mice were euthanized and 2 ml of cold RPMI 1640 (Invitrogen, 
Carmarillo, CA, USA) containing collagenase type V (1 mg/ml; Sigma Aldrich, St Louis, MO, USA) were infused 
into the pancreatic duct in situ. Perfused pancreata were collected in serum-free RPMI medium and kept on ice 
until enzymatic digestion at 37 °C for 12 min. Islets were purified on a discontinuous Ficoll gradient of following 
densities: 1.118, 1.096 and 1.037 g/ml (Cellgro by Mediatech Inc., Manassas, VA, USA) and islets were collected 
between the second and the third fraction. Islets were cultured overnight in a humidified 5% CO2 atmos-
phere at 37 °C in RPMI 1640 medium supplemented with L-glutamine (Sigma Aldrich, St. Louis, MO, USA), 
penicillin-streptomycin (10 mg/ml; Sigma Aldrich) and 10% (v/v) fetal calf serum (HyClone, Celbio, Logan, UT, 
USA). Islets were counted and hand-picked under bright field microscope and 50, 100, 200, 400 or 800 islets were 
transplanted in the calf muscle (n = 5 per group), parallel to the fibula, using needles with a 0.8 mm diameter. 
The exact number of transplanted islets was determined by subtracting the remaining islets in the tube from the 
initially counted number.
Radiolabeling of exendin-3. [Lys 40(DTPA)]-exendin-3 was purchased from Peptide Specialty Laboratories 
(Heidelberg, Germany). Tracer labeling with In-111 was performed as previously described17. Radiochemical 
purity was determined by ITLC and radiolabeled exendin-3 was purified by solid-phase extraction using a 
HLB-column as previously reported17.
SPECT acquisition. Mice with 50, 100, 200, 400 and 800 islets were scanned after 4 weeks. All mice (n = 4–5) 
were injected with approximately 15 MBq of 111In-exendin-3 (peptide dose 0.1 µg in 200 µl PBS, 0.5% BSA) in 
the tail vein. SPECT scans were acquired 1 h post-injection on a U-SPECT-II/CT dedicated small-animal scan-
ner (MILabs, Utrecht, Netherlands) for 50 min with a high sensitivity mouse collimator (1.0 mm pinholes). 
Computed tomography (CT) was performed subsequently for anatomical reference. Standards of 74 kBq, 55 kBq, 
37 kBq and 18 kBq in 50 µl volume each, were scanned under the same parameters as reference for quantification. 
Images were reconstructed with voxel size of 0.4 mm, 3 iterations and 16 subsets, using U-SPECT-II reconstruc-
tion software (MILabs, Utrecht, The Netherlands). The VOI was drawn over the islet transplant region, total 
voxel intensity registered in the islet graft was corrected by the mean of 3 measurements of contra-lateral control 
muscle, to subtract the background signal originating from the muscle tissue. The absolute activity (in kBq) was 
calculated by multiplying the corrected voxel intensity value with the calibration factor determined by quantita-
tive analysis of standards with known radioactivity and data were normalized by the injected dose.
Morphometric analysis of the transplant. Immediately after SPECT acquisitions, mice were euthanized, 
muscles were fixed in 4% paraformaldehyde and embedded in paraffin, then sectioned into 4 µm slices for auto-
radiography analysis or for determination of insulin volume by immunohistochemistry. For autoradiography 
analysis, muscle sections were exposed to an imaging plate (Fuji Film BAS-SE 2025, Raytest, Straubenhardt, 
Germany) for 7 days and images were visualized with a radioluminography laser imager (Fuji Film BAS 1800 
II system, Raytest, Straubenhardt, Germany) and were finally stained with hematoxylin-eosin (HE) to confirm 
the presence of islets. For determination of insulin volume, insulin staining was performed in muscle sections. 
Antigen retrieval was done using 10 mM sodium citrate buffer, pH 6.0, for 10 min (Thermo Scientific PT module, 
Lab Vision, USA). Blocking of endogenous peroxidase activity was performed by incubation with 0.6% H2O2 in 
40% methanol/60% PBS for 30 min at RT in the dark. An additional blocking step was done with 5% swine serum 
in PBS for 30 min at RT. Primary anti-insulin antibody (cat. sc 9168, Santa Cruz Biotechnology, Inc., Santa Cruz, 
CA, USA) was applied at a dilution of 1:50 (in PBS containing 1% BSA w/v). Subsequently, sections were washed 
with PBS and incubated with secondary horseradish peroxidase-conjugated swine-anti-rabbit IgG (1:50) (cat. 
P0217, Dakopatts, Copenhagen, Denmark) in PBS containing 1% BSA w/v for 30 min at RT. The staining was vis-
ualized with diaminobenzidine (PowerVisionTM DAB substrate system, Immunologic, Duiven, The Netherlands) 
and nuclei were counterstained with haematoxylin. To determine the volume of the transplant, sections were 
scanned with Pannoramic250 Flash II scanner (3D Histech, Budapest, Hungary), beta-cell surface was manually 
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drawn around insulin positive region using Photoshop CS6. Finally, the volume was determined by multiplying 
the insulin positive surface per section by the inter-section distance, which is 40 µm.
Statistical analysis. Statistical analyses were performed using with Graphpad Prism 5 (San Diego CA, 
USA). The results were presented as mean ± SEM. Correlations were assessed using a two-tailed Pearson’s corre-
lation coefficient. The level of significance was set at P < 0.05.
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